ECP 2018 Final Programme

Tuesday, 11 Sept 51 ECP 2018 · Bilbao Scientific Programme a Tuesday 003 10:30–11:00 ICCR data Timothy Helliwell, United Kingdom 004 11:00–11:30 Conjunctival melanoma Sarah Coupland, United Kingdom 005 11:30–12:00 Uveal melanoma Robert M. Verdijk, The Netherlands OFP-09 Oral Free Paper Session 08:30–12:00 Room A4 Breast Pathology Chairs: Janina Kulka, Hungary Gabor Cserni, Hungary 001 08:30–08:40 What is the ideal Ki67 hot spot definition in breast cancer? Stephanie Robertson, Sweden M. Lippert, J. Hartman 002 08:40–08:50 Intraoperative diagnosis of breast cancer sentinel lymph nodes by scrape cytology: diagnostic accuracy and cost-effectiveness Ana Villar Fernández, Spain A. Ballén Barragán, J. L. Pérez López, J. M. Ródríguez-Barbero, M. Granados Alamillo, R. Granados Carreño 003 08:50–09:00 Somatostatin receptor expression in neuroendocrine breast cancer Robert Terlevic, Croatia M. Peric Balja, D. Tomas, B. Kruslin, S. Vranic, F. Skenderi, A. Demirovic 004 09:00–09:10 Elastic stains in the evaluation of DCIS with comedo necrosis in breast cancers Tamás Zombori, Hungary G. Cserni 005 09:10–09:20 Transcriptional profiling of endocrine resistant versus sensitive breast cancer uncovers gene expression programmes associated with therapeutic response Caroline Schagerholm, Sweden S. Robertson, K. Govindasamy-Muralidharan, J. Lövrot, X. Chen, J. Hartman 006 09:20–09:30 High reproducibility in Ki67 assessment in luminal breast cancers enabled by French recommendations and digital image analysis Charles Bénière, France R. Rouzier, J.-P. Bellocq, Y. Allory, J.-M. Guinebretière 007 10:30–10:40 Tumour-infiltrating lymphocytes in triple-negative breast cancer correlate with morphology, Bcl2 expression, proliferative activity and menopausal status Marketa Koleckova, Czech Republic Z. Kolar, J. Ehrmann, G. Korinkova, R. Trojanec, I. Uberall 008 10:40–10:50 SOX10 expression in invasive ductal carcinomas of the breast and benign breast tissue Kenrry Chiu, Canada D. Ionescu, M. Hayes 010 11:00–11:10 Comparative analysis of human epidermal growth factor receptor 2 (HER2) testing in breast cancer according to 2007 and 2013 American Society of Clinical Oncology/Col- lege of American Pathologist guideline recommendations (ASCO/CAP) Alejandra Wernicke, Argentina P. De la Iglesia, H. Garcia Rivello 011 11:10–11:20 Doxycycline pre-operatively in early breast cancer Cristian Scatena, Italy M. Ghilli, P. Aretini, M. Menicagli, G. Fanelli, C. Marini, A. Di Paolo, C. M. Mazzanti, M. Roncella, F. Sotgia, M. P. Lisanti, A. G. Naccarato 012 11:20–11:30 Tumour infiltrating lymphocytes (TILs) among multiregional metastases in metastatic breast cancers Luisa Sofía Silva Alcoser, Spain S. Gonçalves-Ribeiro, A. Aula, M. Giner, G. Villacampa, E. Martínez, N. Ciriaco, R. Dienstmann, S. Ramón y Cajal, V. Peg, L. De Mattos-Arruda